Total Payments
$13,397
2024 Payments
$1,510
Companies
30
Transactions
844
Medicare Patients
887
Medicare Billing
$170,462
Payment Breakdown by Category
Food & Beverage$13,365 (99.8%)
Education$32.37 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,365 | 842 | 99.8% |
| Education | $32.37 | 2 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $2,649 | 183 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,777 | 90 | $0 (2024) |
| Alkermes, Inc. | $1,441 | 97 | $0 (2024) |
| Lundbeck LLC | $1,116 | 74 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $726.53 | 58 | $0 (2022) |
| Neurocrine Biosciences, Inc. | $711.28 | 58 | $0 (2024) |
| Vanda Pharmaceuticals Inc. | $676.54 | 37 | $0 (2024) |
| Allergan, Inc. | $583.48 | 49 | $0 (2020) |
| Ironshore Pharmaceuticals Inc. | $490.03 | 7 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $422.89 | 25 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,510 | 87 | Otsuka America Pharmaceutical, Inc. ($274.39) |
| 2023 | $1,490 | 89 | Otsuka America Pharmaceutical, Inc. ($252.39) |
| 2022 | $1,599 | 77 | Janssen Pharmaceuticals, Inc ($407.28) |
| 2021 | $1,340 | 81 | Alkermes, Inc. ($221.83) |
| 2020 | $1,014 | 72 | Janssen Pharmaceuticals, Inc ($144.54) |
| 2019 | $2,538 | 145 | Otsuka America Pharmaceutical, Inc. ($620.47) |
| 2018 | $1,895 | 147 | Otsuka America Pharmaceutical, Inc. ($553.89) |
| 2017 | $2,012 | 146 | Otsuka America Pharmaceutical, Inc. ($631.21) |
All Payment Transactions
844 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $17.60 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/13/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Neuropsychiatry | ||||||
| 12/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Neuropsychiatry | ||||||
| 12/09/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: PSYCHIATRY | ||||||
| 12/06/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: Neuropsychiatry | ||||||
| 12/06/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $0.24 | General |
| Category: Neuropsychiatry | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $19.41 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $15.56 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/15/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $10.87 | General |
| Category: PSYCHIATRY | ||||||
| 11/08/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: Neuropsychiatry | ||||||
| 11/06/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug), ABILIFY MAINTENA | Food and Beverage | In-kind items and services | $14.11 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $12.83 | General |
| Category: Neurology | ||||||
| 11/04/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $15.10 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/30/2024 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $27.95 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 10/29/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: Central Nervous System | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $20.60 | General |
| 10/22/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.77 | General |
| Category: PSYCHIATRY | ||||||
| 10/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: Neuropsychiatry | ||||||
| 10/16/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $10.78 | General |
| Category: Neuroscience | ||||||
| 09/27/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Neuropsychiatry | ||||||
| 09/27/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $0.24 | General |
| Category: Neuropsychiatry | ||||||
| 09/25/2024 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $31.00 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 09/19/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $48.92 | General |
| Category: Neuroscience | ||||||
| 09/17/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.26 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 163 | 684 | $45,080 | $30,572 |
| 2022 | 5 | 245 | 1,067 | $71,240 | $46,894 |
| 2021 | 4 | 258 | 1,240 | $87,430 | $58,983 |
| 2020 | 4 | 221 | 676 | $54,090 | $34,013 |
Total Patients
887
Total Services
3,667
Medicare Billing
$170,462
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 37 | 423 | $16,920 | $12,942 | 76.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 37 | 71 | $14,200 | $8,728 | 61.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 89 | $8,010 | $4,807 | 60.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 37 | 73 | $5,110 | $3,896 | 76.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 20 | 28 | $840.00 | $198.36 | 23.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 51 | 677 | $27,080 | $19,165 | 70.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 53 | 120 | $24,000 | $16,304 | 67.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 55 | 117 | $8,190 | $6,084 | 74.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 38 | 89 | $8,010 | $4,311 | 53.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 27 | 34 | $3,060 | $763.30 | 24.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 21 | 30 | $900.00 | $266.11 | 29.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 68 | 775 | $31,000 | $22,359 | 72.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 70 | 162 | $32,400 | $22,182 | 68.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 70 | 162 | $11,340 | $8,838 | 77.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 50 | 141 | $12,690 | $5,604 | 44.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 49 | 90 | $18,000 | $13,534 | 75.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 45 | 297 | $11,880 | $9,056 | 76.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 58 | 179 | $16,110 | $5,777 | 35.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 50 | 90 | $6,300 | $4,984 | 79.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 19 | 20 | $1,800 | $662.15 | 36.8% |
About Dr. Rex Lear, MD
Dr. Rex Lear, MD is a Psychiatry healthcare provider based in Wichita, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962445999.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rex Lear, MD has received a total of $13,397 in payments from pharmaceutical and medical device companies, with $1,510 received in 2024. These payments were reported across 844 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($13,365).
As a Medicare-enrolled provider, Lear has provided services to 887 Medicare beneficiaries, totaling 3,667 services with total Medicare billing of $170,462. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Wichita, KS
- Active Since 06/14/2006
- Last Updated 05/17/2018
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1962445999
Products in Payments
- REXULTI (Drug) $2,157
- INVEGA SUSTENNA (Drug) $1,486
- ABILIFY MAINTENA (Drug) $1,212
- VRAYLAR (Drug) $981.73
- ARISTADA (Drug) $932.48
- LATUDA (Drug) $726.53
- INGREZZA (Drug) $711.28
- TRINTELLIX (Drug) $536.80
- Aristada 441 mg (Drug) $487.77
- HETLIOZ (Drug) $423.18
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $410.05
- CAPLYTA (Drug) $393.51
- PERSERIS (Drug) $273.77
- SPRAVATO (Drug) $262.92
- AUSTEDO (Drug) $255.68
- Adzenys XR-ODT (Drug) $228.38
- Fanapt (Drug) $209.41
- Dayvigo (Drug) $201.68
- VYVANSE (Drug) $193.65
- Austedo XR (Drug) $154.38
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Wichita
Sheldon Preskorn, Phd, PHD
Psychiatry — Payments: $731,728
Psychiatry $731,728
Dr. Dwight St Clair, Do, DO
Psychiatry — Payments: $44,490
Psychiatry $44,490
Dr. Paul Murphy, M.d, M.D
Psychiatry — Payments: $33,828
Psychiatry $33,828
Dr. Ralph Bharati, Md, MD
Psychiatry — Payments: $25,839
Psychiatry $25,839
Heidi Ogden, Md, MD
Psychiatry — Payments: $22,157
Psychiatry $22,157
Dr. Mukhtar Shah, M.d, M.D
Psychiatry — Payments: $13,680
Psychiatry $13,680